Efficacy and safety comparison of combination of 0.04% tretinoin microspheres plus 1% clindamycin versus their monotherapy in patients with acne vulgaris: a phase 3, randomized, double-blind study

References

• Burton J, Cunliffe W, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971;85(2):119–126.
   PubMed Web of Science ®Google Scholar
• Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172 (Suppl 1):3–12.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4(12):833–842.
   PubMed Web of Science ®Google Scholar
• Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet (London, England). 2012;379(9813):361–372.
   PubMed Web of Science ®Google Scholar
• Kubba R, Bajaj A, Thappa D, et al. Acne in India: Guidelines for management-Introduction. Indian J Dermatol Venereol and Leprol. 2009;75(S1):1–2.
   PubMed Web of Science ®Google Scholar
• Al‐Ameer AM, Al‐Akloby OM. Demographic features and seasonal variations in patients with acne vulgaris in Saudi Arabia: a hospital‐based study. Intl J Dermatol. 2002;41(12):870–871.
   PubMed Web of Science ®Google Scholar
• Tan HH, Tan A, Barkham T, et al. Community‐based study of acne vulgaris in adolescents in Singapore. Br J Dermatol. 2007;157(3):547–551.
   PubMed Web of Science ®Google Scholar
• Adityan B, Thappa DM. Profile of acne vulgaris-A hospital-based study from South India. Indian J Dermatol Venereol Leprol. 2009;75(3):272.
   PubMed Web of Science ®Google Scholar
• Pandey S. Epidemiology of acne vulgaris. Indian J Dermatol. 1983;28(3):109–110.
   PubMedGoogle Scholar
• Nast A, Rosumeck S, Erdmann R, et al. Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne – update 2016. J Eur Acad Dermatol Venereol. 2016;30(8):e1–e28.
   PubMed Web of Science ®Google Scholar
• Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1–29.
   PubMed Web of Science ®Google Scholar
• Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1):S1–S37.
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1–S50.
   PubMed Web of Science ®Google Scholar
• Abdel-Naser MB, Zouboulis CC. Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris. Expert Opin Pharmacother. 2008;9(16):2931–2937.
   PubMed Web of Science ®Google Scholar
• Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3):S200–S210.
   PubMed Web of Science ®Google Scholar
• Jarratt MT, Brundage T. Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study. J Drugs Dermatol. 2012;11(3):318–326.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54(1):73–81.
   PubMed Web of Science ®Google Scholar
• Richter J, Bousema M, Boulle KD, et al. Efficacy of a fixed clindamycin phosphate 1.2%, tretinoin 0.025% gel formulation (Velac) in the topical control of facial acne lesions. J Dermatolog Treat. 1998;9(2):81–90.
   Web of Science ®Google Scholar
• Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol. 1983;22(1):41–43.
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Menter A, Gold M, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607–615.
   PubMedGoogle Scholar
• Yaroshinsky A, Leyden J. The safety and efficacy of clindamycin (1% as clindamycin phosphate and tretinoin (0.025%)] for the treatment of acne vulgaris: a combined analysis of results from six controlled safety and efficacy trials conducted in Europe. J Am Acad Dermatol. 2004;50(3):P23.
   Web of Science ®Google Scholar
• Galvin S, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139:34–40.
   PubMed Web of Science ®Google Scholar
• Luckya AW, Cullenb SI, Jarratt MT, et al. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter, double-blind, parallel study. J Am Acad Dermatol. 1998;38(4):S17–S23.
   PubMed Web of Science ®Google Scholar
• Quigley JW, Bucks DA. Reduced skin irritation with tretinoin containing polyolprepolymer-2, a new topical tretinoin delivery system: a summary of preclinical and clinical investigations. J Am Acad Dermatol. 1998;38(4):S5–S10.
   PubMed Web of Science ®Google Scholar
• Skov MJ, Quigley JW, Bucks DA. Topical delivery system for tretinoin: research and clinical implications. J Pharm Sci. 1997;86(10):1138–1143.
   PubMed Web of Science ®Google Scholar
• Nighland M, Yusuf M, Wisniewski S, et al. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis. 2006;77(5):313–316.
   PubMed Web of Science ®Google Scholar
• Nyirady J, Lucas C, Yusuf M, et al. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis. 2002;70(5):295–298.
   PubMed Web of Science ®Google Scholar
• Dreno B, Bettoli V, Ochsendorf F, et al. Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies. Eur J Dermatol. 2014;24(2):201–209.
   PubMed Web of Science ®Google Scholar
• Culp L, Moradi Tuchayi S, Alinia H, et al. Tolerability of topical retinoids: are there clinically meaningful differences among topical retinoids? J Cutan Med Surg. 2015;19(6):530–538.
   PubMed Web of Science ®Google Scholar
• Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369–381.
   PubMed Web of Science ®Google Scholar